Compare ACOG & STIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACOG | STIM |
|---|---|---|
| Founded | 2000 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.6M | 120.4M |
| IPO Year | 2024 | 2018 |
| Metric | ACOG | STIM |
|---|---|---|
| Price | $8.70 | $2.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $18.00 | $5.75 |
| AVG Volume (30 Days) | 89.3K | ★ 1.2M |
| Earning Date | 11-12-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 41.58 | ★ 57.25 |
| EPS | N/A | ★ N/A |
| Revenue | $10,220,275.00 | ★ $52,776,000.00 |
| Revenue This Year | $152.34 | $8.63 |
| Revenue Next Year | $91.54 | $9.24 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.50 | $0.80 |
| 52 Week High | $10.14 | $3.44 |
| Indicator | ACOG | STIM |
|---|---|---|
| Relative Strength Index (RSI) | 56.15 | 33.58 |
| Support Level | $5.49 | $1.20 |
| Resistance Level | $9.95 | $2.37 |
| Average True Range (ATR) | 0.47 | 0.18 |
| MACD | 0.01 | -0.08 |
| Stochastic Oscillator | 93.62 | 2.17 |
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.